Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-m9kch Total loading time: 0 Render date: 2024-05-18T06:51:11.590Z Has data issue: false hasContentIssue false

174 - Mucormycosis (and entomophthoramycosis)

from Part XXII - Specific organisms: fungi

Published online by Cambridge University Press:  05 April 2015

Scott F. Davies
Affiliation:
Hennepin County Medical Center
David Schlossberg
Affiliation:
Temple University, Philadelphia
Get access

Summary

The term mucormycosis refers to a group of highly lethal angioinvasive fungal infections, mostly in immunocompromised hosts, caused by members of the order Mucorales, which include various species of the genera Rhizopus, Lichtheimia (formerly Absidia), Mucor, and Saksenaea. Other genera of Mucorales have also been implicated in human disease including Cunninghamella, Apophysomyces, and Rhizomucor. Most infections (50%–65% of total) are caused by Rhizopus species.

Classification is in flux because of extensive molecular phylogenetic analysis that has been ongoing for more than 10 years. Note that it is incorrect to use the term mucormycosis to refer only to infections caused by species of the genus Mucor, which are only a small minority of the total number of cases. Rather, mucormycosis refers to infection by any of the organisms within the seven genera of the order Mucorales as noted.

The term entomophthoramycosis refers to infections by members of the separate genera Conidiobolus and Basidiobolus. These organisms generally occur in tropics and cause chronic subcutaneous infection mostly in immunocompeten hosts. Only rarely (less than 15 reported cases) have they ever caused clinical syndromes overlapping with mucormycosis.

For the remainder of this chapter the term mucormycosis will be used to refer to the range of clinical infections caused by organisms in the seven genera of the order Mucorales. In recent usage this term is generally preferred over the term zygomycosis, because of elimination of Zycomycetes from the taxonomic structure and the very different clinical syndrome as compared to entomophthoramycosis with virtually no clinical overlap.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Chamilos, G, Marom, EM, Lewis, RE, Lionakis, MS, Kontoyiannis, PD. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis. 2005;41(1):60–66.CrossRefGoogle ScholarPubMed
Kontoyiannis, DP, Lionakis, MS, Lewis, RE. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191(8):1350–1360.CrossRefGoogle Scholar
Kwon-Chung, KJ.Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin Infect Dis. 2012;54(Suppl 1):S8–S15.CrossRefGoogle ScholarPubMed
Lewandowski, L, Purcell, R, Fleming, M, Gordon, WT. The use of dilute Dakin’s solution for the treatment of angioinvasive fungal infection in the combat wounded: a case series. Mil Med. 2013;178(4):e503–e507.CrossRefGoogle ScholarPubMed
Neblett Fanfair, R, Benedict, K, Bos, J, et al. Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N Engl J Med. 2012;367(23):2214–2225.CrossRefGoogle ScholarPubMed
Pagano, L, Cornely, O, Busca, A, et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematological diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica. 2013;98(10):e127–e130.CrossRefGoogle ScholarPubMed
Roden, MM, Zaoutis, TE, Buchanan, WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634–653.CrossRefGoogle ScholarPubMed
Spellberg, B, Ibrahim, AS, Chin-Hong, PV, et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother. 2012;67(3):715–722.CrossRefGoogle ScholarPubMed
Spellberg, B, Ibrahim, A, Roilides, E, et al. Combination therapy for mucormycosis: why, what, and how?Clin Infect Dis. 2012;54(Suppl 1):S73–S78.CrossRefGoogle Scholar
Van Burik, JA, Hare, RS, Solomon, HF, Corrado, ML, Kontoyiannis, DP.Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis. 2006;42(7):e61–e65.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×